Sunday, March 18, 2018
Company News: Page (1) of 1 - 12/07/17 Email this story to a friend. email article Print this page (Article printing at page facebook
Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

By Globenewswire

CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference at 4:30 p.m. ET on Thursday, December 14, 2017 in New York.

A live webcast of the presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at A replay of the webcast will be archived for 30 days following the presentation.

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long?lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit

Investor Contact:Komal Joshi

Jounce Therapeutics, Inc.
(857) 320-2523
[email protected]  

Media Contact:
Katie Engleman
Pure Communications, Inc.
(910) 509-3977 
[email protected]

Page: 1


Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines